This article is for informational purposes only and does not constitute medical advice. Always consult your gastroenterologist, physician, or healthcare provider before starting any supplement, especially if you have a digestive condition or take medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
MercyIowaCityClinics.org is an independent editorial publication and is not affiliated with any hospital, clinic, or medical provider.
MICC Review Team | July 2026
Zinc Carnosine: Gastric Mucosal Protection and Periodontal Health Profile
Zinc carnosine (also marketed as polaprezinc or carnosine zinc) is a dipeptide-mineral complex showing emerging evidence for gastric mucosal protection and oral health support. Research indicates zinc carnosine may accelerate gastric mucosal healing in H. pylori infection and peptic ulcer disease, while simultaneously supporting gum health and periodontal tissue integrity. The dual-tissue mechanism reflects shared epithelial health pathways in the GI and oral mucosa.
Biochemistry and Mechanism
Zinc carnosine is a molecular complex where carnosine (a dipeptide of beta-alanine and histidine) is bound to zinc. Unlike free zinc supplementation, the carnosine moiety acts as a carrier that enhances absorption and targets the compound to damaged mucosal tissues. In the stomach, zinc carnosine accumulates at sites of mucosal injury, stimulating mucin production, promoting mucosal blood flow, and inhibiting gastric acid secretion at lesion sites. The carnosine peptide itself offers antioxidant protection, reducing inflammatory cytokine production. This mechanism applies similarly to oral mucosa, where zinc and carnosine both support fibroblast proliferation and collagen synthesis essential for gum health.
Gastric Health Research Evidence
| GI Application | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| H. pylori infection and peptic ulcer healing | Moderate | RCTs, open-label trials from Asia | 75 mg twice daily for 4–8 weeks |
| Gastric mucosal bleeding and erosive gastritis | Preliminary | Small observational studies | 75 mg daily to twice daily |
| Oral health and periodontal disease | Preliminary | Small RCTs, pilot studies | 50–75 mg daily for 8–12 weeks |
A 2018 systematic review examining zinc carnosine for H. pylori and peptic ulcer disease found that supplementation as adjunct to standard triple therapy (antibiotics + PPI) accelerated mucosal healing by 2–3 weeks compared to standard therapy alone. Endoscopic ulcer size reduction was significantly greater with zinc carnosine. However, most trials were conducted in Asian populations; replication in Western cohorts is limited. For oral health, preliminary RCTs suggest zinc carnosine may reduce bleeding on probing and improve gum recession in periodontitis patients when combined with conventional treatment, though evidence is not yet robust enough for clinical guideline recommendation.
Dose Comparison: Research vs. Market
Clinical trials used 75 mg zinc carnosine daily or divided into 75 mg twice daily (150 mg total). Most commercial supplements deliver 50–75 mg per dose. The molecular weight ratio means 75 mg zinc carnosine provides approximately 17 mg of elemental zinc. This is lower than typical zinc supplementation (25–50 mg elemental) but targets the compound's bioavailability advantage. Dosing aligns reasonably well between clinical research and available products, though optimal duration and timing (with or without food) vary across studies.
Forms and Bioavailability Considerations
Zinc carnosine (polaprezinc) is primarily available as a proprietary complex in tablet or capsule form. Unlike elemental zinc salts (gluconate, picolinate), the carnosine chelation enhances intestinal absorption and reduces gastric irritation. Polaprezinc, the Japan-approved form, has the most clinical trial support. Enteric-coated or delayed-release formulations are sometimes used to minimize stomach irritation, though the complex is generally well-tolerated even on an empty stomach. Taking zinc carnosine apart from high-dose iron or calcium supplements optimizes absorption.
Drug Interactions and Safety Profile
PPI interactions: Omeprazole and other PPIs reduce gastric acidity, which may slightly decrease zinc carnosine absorption; however, the compound's chelation structure mitigates this risk compared to free zinc. Antibiotics and H. pylori treatment: Zinc carnosine is used as an adjunct to triple therapy (amoxicillin, clarithromycin, PPI) or quadruple therapy with no documented significant interactions; timing separation is not required. Iron and calcium: Both may compete for absorption; if supplementing simultaneously, separate dosing by 2+ hours. Immunocompromise: No elevated risk reported, though high-dose zinc (>50 mg elemental daily long-term) can impair immune function; zinc carnosine's lower elemental zinc load reduces this concern. Pregnancy and lactation: Insufficient safety data; use only under medical supervision.
Who Should Consider and Who Should Avoid
Candidates for zinc carnosine: Patients with H. pylori infection on standard triple therapy seeking accelerated mucosal healing, those with chronic erosive or bleeding gastritis, patients with peptic ulcer disease, and individuals with gingivitis or periodontitis seeking adjunctive support for gum healing. Use caution in: Patients with copper deficiency (zinc can impair copper absorption over time), those with acute kidney disease requiring mineral monitoring, and patients on high-dose zinc supplementation from other sources. Avoid if: Severe immunocompromise or documented zinc toxicity.
Clinical Bottom Line
Zinc carnosine shows moderate evidence for accelerating gastric mucosal healing in H. pylori infection and peptic ulcer disease when used adjunctively with standard medical therapy. Emerging data supports a complementary role in oral health, particularly for periodontal disease. The dual mechanism—targeting gastric and oral epithelial tissues—reflects genuine tissue-protective biology rather than marketing. However, it is not a replacement for eradication therapy in H. pylori or essential dental care for periodontitis. Understanding the role of mucosal protectants in overall gut health strategy remains important for comprehensive gastrointestinal care.
This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified gastroenterologist, physician, or healthcare provider. Patients with digestive conditions should discuss all supplement use with their GI care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. MercyIowaCityClinics.org is an independent editorial publication and is not affiliated with any hospital, clinic, or medical provider.